Windtree Therapeutics Stock Analysis

WINT Stock  USD 1.65  0.11  6.25%   
Windtree Therapeutics is undervalued with Real Value of 3.02 and Target Price of 7.0. The main objective of Windtree Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Windtree Therapeutics is worth, separate from its market price. There are two main types of Windtree Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Windtree Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Windtree Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Windtree Stock trading window is adjusted to America/New York timezone.
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Windtree Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Windtree Stock please use our How to Invest in Windtree Therapeutics guide.

Windtree Stock Analysis Notes

The company has Price to Book (P/B) ratio of 0.3. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Windtree Therapeutics recorded a loss per share of 19.03. The entity last dividend was issued on the 29th of April 2020. The firm had 1:18 split on the 22nd of April 2024. Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Windtree Therapeutics, Inc. is a subsidiary of Lees Pharmaceutical Holdings Limited. Windtree Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people. For more information please call Craig Fraser at 215 488 9300 or visit https://windtreetx.com.

Windtree Therapeutics Investment Alerts

Windtree Therapeutics generated a negative expected return over the last 90 days
Windtree Therapeutics has high historical volatility and very poor performance
Windtree Therapeutics may become a speculative penny stock
Windtree Therapeutics has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (20.29 M) with loss before overhead, payroll, taxes, and interest of (17.79 M).
Windtree Therapeutics currently holds about 11.38 M in cash with (13.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37.
Windtree Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from benzinga.com: Whats Going On With Windtree Therapeutics Stock

Windtree Therapeutics Upcoming and Recent Events

1st of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Windtree Largest EPS Surprises

Earnings surprises can significantly impact Windtree Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-05-15
2024-03-31-0.94-0.740.221 
2024-03-29
2023-12-31-0.94-0.740.221 
2023-11-09
2023-09-30-0.63-0.86-0.2336 
View All Earnings Estimates

Windtree Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Blackrock Inc2024-12-31
6.0
Royal Bank Of Canada2024-12-31
2.0
Activest Wealth Management2024-12-31
2.0
Northern Trust Investments N A2024-12-31
0.0
Morgan Stanley - Brokerage Accounts2024-12-31
0.0
Armistice Capital, Llc2024-12-31
0.0
Ifp Advisors, Llc2024-12-31
0.0
Renaissance Technologies Corp2024-12-31
119.3 K
Ubs Group Ag2024-12-31
59.6 K
Geode Capital Management, Llc2024-12-31
59.2 K
Xtx Topco Ltd2024-12-31
19.5 K
Note, although Windtree Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Windtree Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.92 M.

Windtree Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(3.26)(3.42)
Return On Capital Employed(0.56)(0.58)
Return On Assets(0.72)(0.76)
Return On Equity(6.88)(6.54)

Management Efficiency

Windtree Therapeutics has return on total asset (ROA) of (0.4476) % which means that it has lost $0.4476 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.508) %, meaning that it created substantial loss on money invested by shareholders. Windtree Therapeutics' management efficiency ratios could be used to measure how well Windtree Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -3.42 in 2025. Return On Capital Employed is likely to drop to -0.58 in 2025. At this time, Windtree Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 42.3 M in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 16.4 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 17.73  16.84 
Tangible Book Value Per Share(114.26)(108.55)
Enterprise Value Over EBITDA(0.93)(0.98)
Price Book Value Ratio 2.81  2.67 
Enterprise Value Multiple(0.93)(0.98)
Price Fair Value 2.81  2.67 
Enterprise ValueB951.8 M
Leadership effectiveness at Windtree Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta
0.643
Return On Assets
(0.45)
Return On Equity
(1.51)

Technical Drivers

As of the 25th of March, Windtree Therapeutics maintains the Mean Deviation of 6.33, standard deviation of 9.4, and Market Risk Adjusted Performance of (103.65). Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Windtree Therapeutics, as well as the relationship between them.

Windtree Therapeutics Price Movement Analysis

Execute Study
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Windtree Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Windtree Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Windtree Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Windtree Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Windtree Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Windtree Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Craig Fraser over two weeks ago
Acquisition by Craig Fraser of 68800 shares of Windtree Therapeutics at 1.21 subject to Rule 16b-3
 
Craig Fraser over three weeks ago
Acquisition by Craig Fraser of 500 shares of Windtree Therapeutics at 2.57 subject to Rule 16b-3
 
Steven Simonson over three weeks ago
Disposition of 100 shares by Steven Simonson of Windtree Therapeutics subject to Rule 16b-3
 
Craig Fraser over a month ago
Disposition of 334 shares by Craig Fraser of Windtree Therapeutics subject to Rule 16b-3
 
Huang James over two months ago
Disposition of 275938 shares by Huang James of Windtree Therapeutics at 12.09 subject to Rule 16b-3
 
Craig Fraser over three months ago
Acquisition by Craig Fraser of 500 shares of Windtree Therapeutics at 2.4587 subject to Rule 16b-3
 
Bioengine Capital Inc. over three months ago
Disposition of 249004 shares by Bioengine Capital Inc. of Windtree Therapeutics at 12.15 subject to Rule 16b-3
 
Craig Fraser over three months ago
Acquisition by Craig Fraser of 5431 shares of Windtree Therapeutics at 0.9099 subject to Rule 16b-3
 
Huang James over six months ago
Acquisition by Huang James of 1112308 shares of Windtree Therapeutics at 0.1411 subject to Rule 16b-3
 
Latkin Jed over six months ago
Insider Trading
 
Craig Fraser over six months ago
Acquisition by Craig Fraser of 2000 shares of Windtree Therapeutics at 0.9799 subject to Rule 16b-3
 
Craig Fraser over six months ago
Acquisition by Craig Fraser of 3000 shares of Windtree Therapeutics at 1.9 subject to Rule 16b-3

Windtree Therapeutics Outstanding Bonds

Windtree Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Windtree Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Windtree bonds can be classified according to their maturity, which is the date when Windtree Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Windtree Therapeutics Predictive Daily Indicators

Windtree Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Windtree Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Windtree Therapeutics Forecast Models

Windtree Therapeutics' time-series forecasting models are one of many Windtree Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Windtree Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Windtree Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Windtree Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Windtree shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Windtree Therapeutics. By using and applying Windtree Stock analysis, traders can create a robust methodology for identifying Windtree entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(124.89)(131.13)
Operating Profit Margin(144.58)(137.35)
Net Loss(173.44)(164.77)
Gross Profit Margin 0.84  0.88 

Current Windtree Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Windtree analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Windtree analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
7.0Hold1Odds
Windtree Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Windtree analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Windtree stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Windtree Therapeutics, talking to its executives and customers, or listening to Windtree conference calls.
Windtree Analyst Advice Details

Windtree Stock Analysis Indicators

Windtree Therapeutics stock analysis indicators help investors evaluate how Windtree Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Windtree Therapeutics shares will generate the highest return on investment. By understating and applying Windtree Therapeutics stock analysis, traders can identify Windtree Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow6.3 M
Total Stockholder Equity3.4 M
Capital Lease Obligations1.6 M
Property Plant And Equipment Net1.6 M
Cash And Short Term Investments4.3 M
Net Invested Capital3.6 M
Cash4.3 M
50 Day M A1.696
Net Interest Income275 K
Total Current LiabilitiesM
Forward Price Earnings0.3652
Investments-15 K
Interest Expense50 K
Stock Based Compensation1.3 M
Common Stock Shares Outstanding220 K
Free Cash Flow-13.5 M
Other Current Assets1.1 M
Accounts Payable809 K
Net Debt12.5 M
Depreciation82 K
Other Operating Expenses17.5 M
Non Current Assets Total27 M
Liabilities And Stockholders Equity32.4 M
Non Currrent Assets Other150 K

Additional Tools for Windtree Stock Analysis

When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.